Biosurgical Agents | Market Insights | US | 2022
The COVID-19 pandemic has negatively impacted the US biosurgical agent market due to the deferral or cancelation of elective and semielective procedures. Although the market is impacted in the short term by the COVID-19 pandemic, the biosurgical agent market in the US will grow at a modest rate through 2030, primarily driven by growing surgical procedure volumes, rising awareness of the clinical benefits of these products on surgical outcomes, and the introduction of new products with enhanced features and expanded indications. However, growing concerns over product cost will limit ASP growth in this market, thus hindering revenue expansion to some extent.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for biosurgical agents in the US across an 11-year period.
